Page 91 of 104
The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which ...
A relatively small number of cells in the normal human mammary gland express receptors for oestrogen and progesterone (ER and PR), and there is almost complete dissociation between steroid receptor expression ...
The progesterone receptor knockout mouse demonstrated progesterone's importance to parity-induced mammary tertiary branching and lobuloalveologenesis. Because early parity provides significant protection again...
Progesterone is an essential regulator of normal female reproductive function. Its effects are mediated by two nuclear progesterone receptor (PR) proteins, PRA and PRB, which are identical except for an additi...
Progesterone, an ovarian steroid hormone, plays a key role in the development and function of the mammary gland, as it also does in the uterus and the ovary. The action of progesterone is mediated through its ...
A recent analysis by the Collaborative Group on Hormonal Factors in Breast Cancer has provided the most precise quantification to date of the familial risks of breast cancer. The familial relative risks are sh...
Human ductal carcinoma in situ (DCIS) of the breast is now diagnosed quite frequently, due largely to the introduction of mammographic screening. It has been shown in a cell culture system that activation of c-er...
The transcription factor NF-κB exhibits altered activity in some breast cancers but the relevance of this association has not been established. Cao et al.'s elegant study recently published in Cell reveals a NF-κ...
Epithelial/mesenchymal cell interactions are necessary for proper ductal morphogenesis throughout all stages of mammary gland development. Besides the well-established stromal components, such as adipocytes an...
High-throughput screening is an essential component of the toolbox of modern technologies that improve speed and efficiency in contemporary cancer drug development. This is particularly important as we seek to...
Cyclin E, a key mediator of entry into the cell division cycle, is expressed abundantly in many breast cancers. However, amplification of the cognate gene is observed rarely, leaving the responsible mechanism(...
Recent reports detailing the expression profiles of primary breast cancer have pointed to the utility of this approach in defining subclasses with distinct molecular configurations and clinical behaviour. Some...
Maspin is a member of the serpin family of serine proteases and functions as a tumour suppressor. A study using a new syngeneic mouse model for breast cancer suggests that maspin can inhibit metastasis in vivo.
High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen. Subsequently, the use of estrogen was largely aba...
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
This article is part of a Supplement: Volume 4 Supplement 1
2022 Citation Impact
7.4 - 2-year Impact Factor
7.4 - 5-year Impact Factor
1.764 - SNIP (Source Normalized Impact per Paper)
2.408 - SJR (SCImago Journal Rank)
2023 Speed
20 days submission to first editorial decision for all manuscripts (Median)
129 days submission to accept (Median)
2023 Usage
2,432,781 downloads
1,561 Altmetric mentions